Title Aprea Therapeutics Receives FDA Approval for APR1051 WEE1 Kinase Inhibitor Targeting Cyclin E Overexpressing Cancers
Aprea Therapeutics has recently been granted FDA approval for its Investigational New Drug (IND) application for APR-1051, a cutting-edge WEE1 ...
